Tue, May 31, 2011
Mon, May 30, 2011
Fri, May 27, 2011
Thu, May 26, 2011
Wed, May 25, 2011
Tue, May 24, 2011
Mon, May 23, 2011
Sun, May 22, 2011
Fri, May 20, 2011
Thu, May 19, 2011
Wed, May 18, 2011
Tue, May 17, 2011
Mon, May 16, 2011
Sun, May 15, 2011
[ Sun, May 15th 2011 ] - Market Wire
Teva to Acquire Taiyo
Fri, May 13, 2011
Thu, May 12, 2011
Wed, May 11, 2011
Tue, May 10, 2011
Mon, May 9, 2011
Sun, May 8, 2011
Sat, May 7, 2011
Fri, May 6, 2011
Thu, May 5, 2011
Wed, May 4, 2011
Tue, May 3, 2011

Alkermesa? Corporate Presentation to be Webcast at the UBS Global Specialty Pharmaceuticals Conference


//health-fitness.news-articles.net/content/2011/ .. global-specialty-pharmaceuticals-conference.html
Published in Health and Fitness on Tuesday, May 17th 2011 at 13:05 GMT by Market Wire   Print publication without navigation


WALTHAM, Mass.--([ BUSINESS WIRE ])--[ Alkermes, Inc. ] (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the UBS Global Specialty Pharmaceuticals Conferenceon Tuesday, May 24, 2011, at 11:00 a.m. BST (6:00 a.m. ET) from the UBS offices in London. The presentation may be accessed under the investor relations tab at [ www.alkermes.com ] and will be archived for 14 days.

Alkermes, Inc. is a fully integrated biotechnology company committed to developing innovative medicines to improve patients' lives. Alkermes developed, manufactures and commercializes VIVITROL® for alcohol and opioid dependence and manufactures RISPERDAL® CONSTA® for schizophrenia and bipolar I disorder. Alkermes' robust pipeline includes extended-release injectable and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Waltham, Massachusetts, Alkermes has a research facility in Massachusetts and a commercial manufacturing facility in Ohio.


Publication Contributing Sources